文献类型：期刊文献

英文题名：Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

作者：Xu, Yuxin[1];Zheng, Wenyun[2];Wang, Tianwen[3];Wang, Ping[1];Zhu, Ling[1];Ma, Xingyuan[1]

机构：[1]E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Biotechnol, Shanghai 200237, Peoples R China;[2]E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Pharm, Shanghai 200237, Peoples R China;[3]Jiangnan Univ, Minist Educ, Key Lab Ind Biotechnol, Sch Biotechnol, Wuxi 214122, Jiangsu, Peoples R China

年份：2012

卷号：66

期号：5

起止页码：368

外文期刊名：BIOMEDICINE & PHARMACOTHERAPY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000307772100007)】；

基金：This work was supported by the National Natural Science Foundation (30873190), the National Science Research Project "Significant New Drugs Created" of Eleventh Five-year Plan (2009ZX09103-693) and Key for Fundamental and Interdisciplinary Research of Chinese Ministry (WK0913002).

语种：英文

外文关键词：Genetic protein TmSm(T34A); Enhancing sensitivity; Chemotherapeutic agent; Breast cell lines

摘要：In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy. (C) 2012 Elsevier Masson SAS. All rights reserved.